Search the Newsreel

147,000 Shares in ImmunityBio, Inc. $IBRX Purchased by Hussman Strategic Advisors Inc.

Hussman Strategic Advisors Inc. acquired 147,000 shares of ImmunityBio, Inc. (IBRX) during the second quarter, valued at approximately $1.29 million. Institutional investors now hold 8.58% of the company, while corporate insiders own 66.10%, despite recent insider selling totaling about $3.92 million. ImmunityBio reported a …

Renaissance Technologies LLC Invests $1.02 Million in Immunic, Inc. $IMUX

Renaissance Technologies LLC has acquired 919,164 shares of Immunic, Inc. (NASDAQ:IMUX) valued at approximately $1.02 million, giving it a 6.75% stake in the biopharmaceutical company. Immunic, which develops oral therapies for autoimmune diseases, recently reported better-than-expected quarterly earnings and maintains a consensus "Buy" rating …

Immunome (NASDAQ:IMNM) Stock Rating Lowered by Wall Street Zen

Wall Street Zen has downgraded Immunome (NASDAQ:IMNM) to a "strong sell" rating, contrasting with the broader analyst consensus of "Moderate Buy" and a price target of $34.64. This downgrade follows Immunome reporting a quarterly loss of $0.65 per share, missing estimates, with full-year losses …

IBRX Stock Eyes Green Open Ahead Of Earnings — What Happened With Anktiva Over The Weekend

Dimensional Fund Advisors LP Sells 103,356 Shares of Immunovant, Inc. $IMVT

Dimensional Fund Advisors LP significantly reduced its stake in Immunovant, Inc. (NASDAQ:IMVT) by selling 103,356 shares, retaining 57,086 shares valued at $1.42 million. This comes as Immunovant's insiders, including the CTO and COO, also sold a substantial number of shares recently. Analysts currently rate …

IBRX Stock Extends Rally To Day 3: Founder Drops ‘Prelude’ To 2025 Earnings, Slams Bristol Myers, Amgen Cancer Playbook

IBRX Stock To Open Week On A High? Chairman Teases Anktiva’s 3-Year Expansion Plans, Hints At Cancer Breakthrough

Nasdaq, S&P 500 Futures Rise Ahead Of Nvidia Earnings, Fed Minutes: Why TSLA, SLS, IBRX, CAVA, POET, BA Are In Focus

ImmuCell Corporation - Common Stock (ICCC) Stock Price, News, Quote & History

Why Immunovant (IMVT) Is Up 5.2% After Wider Q1 Loss, Moderna Cash, And Pivotal Data Hype

Lyell Immunopharma (LYEL): Foresite funds and Tananbaum report 2.7% ownership

Foresite Capital-affiliated funds and James B. Tananbaum have reported a beneficial ownership of 653,328 shares of Lyell Immunopharma (LYEL) common stock, representing 2.7% of the class. This disclosure was made in an updated SCHEDULE 13G/A SEC filing. The ownership is primarily held by Foresite …

ImmuCell Corporation 2026 Q2 - Results - Earnings Call Presentation (NASDAQ:ICCC) 2026-08-14

Cormorant Asset Management (MLTX) discloses 4.35% MoonLake Immunotherapeutics stake

Cormorant Asset Management, LP and Bihua Chen have disclosed a 4.35% beneficial ownership stake in MoonLake Immunotherapeutics (MLTX), totaling 3,205,433 Class A ordinary shares. This stake, reported via a SCHEDULE 13G/A filing, indicates shared voting and dispositive power over the shares and is based …

T. Rowe Price Investment Management (IMNM) discloses 17.4% Immunome ownership, key fund at 6.5%

T. Rowe Price Investment Management, Inc. has reported a beneficial ownership of 17.4% of Immunome, Inc. common stock, totaling 19,676,883 shares, according to a recent SEC filing. The firm holds sole voting power over 19,656,814 shares and sole dispositive power over all 19,676,883 shares. …

ImmuCell Q2 2026 slides: revenue gains offset by margin pressure

ImmuCell (NASDAQ:ICCC) reported mixed Q2 2026 results, with product sales up 11.5% to $7.2 million, but gross margin significantly compressed from 43.7% to 33.9%. Despite a tripling of net income to $1.8 million largely due to a $2 million legal settlement, the stock dropped …

ImmuCell Corporation - Common Stock ICCC

ImmuCell Corporation (ICCC) is a biotechnology company focused on veterinary products, particularly for enhancing immune health in livestock. The company's stock recently traded at $10.20, down 6.47%, and has a market cap of $78.93 million. Recent news highlights include Q2 2026 earnings results, increased …

ImmuCell Q2 Earnings Call Highlights

Key Points Interested in ImmuCell Corporation? Here are five stocks we like better. Strong domestic growth drove results: Second-quarter product sales rose 11.5% year over year to $7.2 million, while net income increased to $1.8 million from $500,000. Domestic sales grew 27.7%, offsetting a …

Estrella Immunopharma (ESLA): Armistice Capital discloses 4.99% ownership stake

Armistice Capital, LLC and Steven Boyd have disclosed a 4.99% beneficial ownership stake in Estrella Immunopharma, Inc. (ESLA) common stock. This translates to 2,051,409 shares, over which they hold shared voting and dispositive power. The shares are held by Armistice Capital Master Fund Ltd., …

Earnings call transcript: ImmuCell posts strong Q2 2026 sales growth, shares fall

Deep Track reports 7.99M-share, 9.74% stake in MoonLake (MLTX) in 13G/A

Deep Track Capital, LP, Deep Track Biotechnology Master Fund, Ltd., and David Kroin have filed an amended Schedule 13G/A, reporting a collective beneficial ownership of 7,999,025 Class A ordinary shares, representing a 9.74% stake in MoonLake Immunotherapeutics (MLTX). This ownership includes 1,000,000 Pre-Funded Warrants, …

HC Wainwright Issues Negative Forecast for Immunome Earnings

How Investors May Respond To Immunocore (IMCR) Turning First-Half Profit Amid Recent Share Price Pullback

Immunocore Holdings plc reported a significant improvement in its financial performance, achieving profitability in the first half of 2026 with net income of US$12.16 million, up from a loss the previous year. This positive shift is driven by increased revenue, though the company's investment …

Sirenia Capital discloses 4.3% Immunome (IMNM) stake in Schedule 13G/A

Sirenia Capital Management LP and Alex Silverstein have reported a 4.3% beneficial ownership stake in Immunome Inc. (IMNM) through an amended Schedule 13G filing. They collectively hold 4,832,279 shares of common stock, representing 4.3% of the 113,250,394 shares outstanding as of May 7, 2026. …

ImmuneOnco Sets August Board Meeting to Approve Interim Results and Mull Dividend

Altimmune (ALT) President and CEO Jerome Durso Buys 15,000 Shares

Altimmune Inc.'s President and CEO, Jerome Durso, recently purchased 15,000 shares of the company's stock, increasing his direct ownership to 62,500 shares. This transaction is part of a larger trend of insider buying at Altimmune, with 11 insider buys and no sells in the …

ImmuCell (NASDAQ:ICCC) Announces Earnings Results, Beats Estimates By $0.15 EPS

ImmuCell (NASDAQ:ICCC) reported its earnings results, beating the consensus estimate by $0.15 EPS with reported earnings of $0.20 per share. The biotechnology company also surpassed revenue expectations, bringing in $7.19 million against an anticipated $5.40 million. Despite these positive financial results, the company maintains …

Estrella Immunopharma, Inc. 2Q 2026: Net loss $(2.31M), EPS $(0.05) — 10-Q Summary

Estrella Immunopharma, Inc. reported a net loss of $(2.31M) for the second quarter of 2026, with a loss per share of $(0.05). The company remains pre-revenue, driven by ongoing development and corporate expenses. Key highlights include progress in clinical trials, significant milestones in a …

IMMUCELL CORP /DE/ Q2 2026: Revenue $7.19M, EPS $0.2— 10-Q Summary

IMMUCELL CORP /DE/ (ICCC) reported strong second-quarter 2026 results, with revenue reaching $7.19M and diluted EPS of $0.20, significantly up from the previous year. This growth was primarily driven by increased volumes and pricing for its First Defense product, which accounted for over 99% …

ImmuCell Plans About $4.5M Expansion for Calf Health Products

ImmuCell (NASDAQ: ICCC) reported strong Q2 2026 financial results with product sales up 11.5% to $7.2 million and net income rising to $1.8 million, aided by a $2 million legal settlement. The company announced a two-phase, approximately $8.0 million expansion of its First Defense® …

ImmuCell Corporation (ICCC) doubles profit on higher First Defense sales

ImmuCell Corporation reported robust financial results for the first half of 2026, with net income doubling to $3.8 million due to increased First Defense sales and a significant $2.0 million settlement. The company's product sales grew by 20.9% to $17.5 million, largely driven by …

Altimmune (ALT) CEO Jerome Durso purchases 15,000 shares at $2.95 each

Altimmune, Inc.'s President and CEO, Jerome Benedict Durso, purchased 15,000 shares of the company's common stock at $2.95 per share on August 13, 2026. This transaction, conducted in the open market or a private transaction, increased his direct holdings to 62,500 shares. The Form …

ALT's Q2 Loss Narrower Than Expected, Pemvidutide's Studies in Focus

Altimmune (ALT) reported a narrower-than-expected loss of 12 cents per share in Q2 2026, beating the Zacks Consensus Estimate of 15 cents. The company, which currently has no marketed drugs, focused on advancing its lead candidate, pemvidutide, with ongoing clinical studies for MASH, AUD, …

AC Immune takes Parkinson's vaccine into US trials as Phase II data near

AC Immune SA's experimental alpha-synuclein vaccine, ACI-7104, has received US FDA clearance for its IND and Fast Track Designation for early-stage Parkinson's disease. This allows the vaccine to expand into US clinical development, as it approaches key Phase II data. Interim Phase II results …